Besides, EGFR tyrosine kinase inhibitors (EGFR-TKIs) are among the chemotherapeutics that are commonly used for the treatment of patients with advanced NSCLC adenocarcinoma [69]. Here, EGFR is linked to non-small cell lung carcinoma.